Lamivudine/tenofovir

Lamivudine/tenofovir disoproxil, sold under the brand name Cimduo among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS in adults and children weighing more than 35 kilograms (77 lb).^[1][3] It contains lamivudine and tenofovir disoproxil.^[1] It is taken by mouth.^[1]

Lamivudine/tenofovir

Combination of
Lamivudine	Nucleoside reverse transcriptase inhibitor
Tenofovir disoproxil	Nucleotide reverse transcriptase inhibitor
Clinical data
Trade names	Cimduo, Temixys
AHFS/Drugs.com	Monograph
MedlinePlus	a618039
License data	US DailyMed: Cimduo
Routes of administration	By mouth
ATC code	J05AR12 (WHO)
Legal status
Legal status	US: ℞-only[1][2]
Identifiers
KEGG	D11395

Lamivudine/tenofovir was approved for medical use in the United States in February 2018.^[1][4]